Atopic dermatitis (AD), often called eczema, is a chronic inflammatory skin condition affecting millions of Canadians. It’s characterized by dry, itchy, and inflamed skin that can significantly impact quality of life. While AD can affect anyone, it commonly starts in childhood and may persist into adulthood.
Despite multiple treatment options—like topical corticosteroids, moisturizers, and newer biologics—many patients still experience flares and ongoing symptoms, highlighting gaps in management. This is where newer therapies, such as topical PDE4 inhibitors, can play a role, especially for patients who aren’t responding well to standard care.
Why Clinicians Should Pay Attention
- Misconceptions are common: Patients often underuse therapies or worry about side effects, while providers may not be fully aware of newer options.
- Patient counseling is critical: Proper application, expected outcomes, and realistic timelines can make a big difference in adherence and satisfaction.
- Identifying candidates for PDE4 inhibitors: Knowing who may benefit helps optimize care and reduce flares.
The free course “Atopic Dermatitis: Myth Busters and Dispelling Misinformation” offers a concise, 30-minute overview. Two experienced clinicians walk through the limitations of current treatments, practical prescribing guidance, and tips for effective patient counseling.
It’s an easy way for pharmacists, physicians, nurses, and allied health professionals to update their knowledge and improve patient outcomes.
This program has received an unrestricted educational grant or in-kind support from Arcutis Canada Inc.